• Akari Therapeutics announced new preclinical results for its lead TROP2-targeting antibody-drug conjugate AKTX-101, with findings already presented in an online abstract tied to the ASCO Annual Meeting 2026.
• Studies in KRAS-mutated pancreatic cancer models showed AKTX-101 boosted the anti-tumor effect of the KRAS inhibitor adagrasib, supporting a potential combination strategy in hard-to-treat KRAS-driven disease.
• The company highlighted that similar synergy was not seen with competing TROP2 ADCs that use topoisomerase I inhibitor payloads, a positioning point for AKTX-101’s RNA splicing-modulating PH1 payload.
• The readout also broadened the strategic rationale for AKTX-101 beyond its current Phase 1 plan, with first-in-human trial start targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.